The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | OPERA: contact X-ray brachytherapy in addition to CRT in organ preservation for rectal cancer
Jean-Pierre Gerard, MD, Centre Antoine Lacassagne, Nice, France, presents three-year data from the Phase III OPERA trial (NCT02505750), which investigated the efficacy of contact X-ray brachytherapy (CXB) in addition to chemoradiotherapy in organ preservation for rectal adenocarcinoma. 144 patients were recruited and given chemoradiotherapy followed by CXB or external beam radiotherapy (EBRT). At three-year follow-up, CXB with chemoradiotherapy improved the likelihood of organ preservation, especially if the tumor is less than 3cm in diameter. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
